MX359241B - Preparación inyectable que comprende una composición en gel que comprende aripiprazol o brexpiprazol como agentes de suspensión. - Google Patents

Preparación inyectable que comprende una composición en gel que comprende aripiprazol o brexpiprazol como agentes de suspensión.

Info

Publication number
MX359241B
MX359241B MX2014012811A MX2014012811A MX359241B MX 359241 B MX359241 B MX 359241B MX 2014012811 A MX2014012811 A MX 2014012811A MX 2014012811 A MX2014012811 A MX 2014012811A MX 359241 B MX359241 B MX 359241B
Authority
MX
Mexico
Prior art keywords
injectable preparation
composition
present
pascal
viscosity
Prior art date
Application number
MX2014012811A
Other languages
English (en)
Other versions
MX2014012811A (es
Inventor
Hoshika Yusuke
Kaneko Daiki
Matsuda Takakuni
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX359241(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2014012811A publication Critical patent/MX2014012811A/es
Publication of MX359241B publication Critical patent/MX359241B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un objeto de la presente invención es brindar una preparación inyectable estable durante el almacenamiento que comprende una composición que comprende un fármaco poco soluble como ingrediente activo, y que además comprende un medio de dispersión. Otro objeto de la presente invención es brindar una jeringa prellenada compacta, liviana mediante el envasado de la preparación inyectable en una jeringa. La presente invención proporciona una preparación inyectable que comprende una composición que comprende un fármaco poco soluble, un medio de dispersión y un agente de suspensión específico, la composición tiene una viscosidad de 40 Pa•s o más en, al menos, un punto en el rango de velocidad de corte que oscila entre 0.01 y 0.02 s-1 y tiene una viscosidad de 0.2 Pa•s o inferior, en al menos un punto en el rango de velocidad de corte que oscila entre 900 y 1,000 s-1, como se ha medido.
MX2014012811A 2012-04-23 2013-04-23 Preparación inyectable que comprende una composición en gel que comprende aripiprazol o brexpiprazol como agentes de suspensión. MX359241B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636938P 2012-04-23 2012-04-23
US201361792089P 2013-03-15 2013-03-15
PCT/JP2013/062683 WO2013162048A1 (en) 2012-04-23 2013-04-23 Injectable preparation

Publications (2)

Publication Number Publication Date
MX2014012811A MX2014012811A (es) 2015-05-07
MX359241B true MX359241B (es) 2018-09-20

Family

ID=48614096

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012811A MX359241B (es) 2012-04-23 2013-04-23 Preparación inyectable que comprende una composición en gel que comprende aripiprazol o brexpiprazol como agentes de suspensión.

Country Status (32)

Country Link
US (8) US20150093442A1 (es)
EP (2) EP2841054B2 (es)
JP (6) JP6234996B2 (es)
KR (4) KR20210116702A (es)
CN (3) CN114344259B (es)
AR (1) AR090776A1 (es)
AU (4) AU2013253374B2 (es)
BR (1) BR112014026307B1 (es)
CA (2) CA3120297A1 (es)
CO (1) CO7151500A2 (es)
CY (1) CY1122252T1 (es)
DK (1) DK2841054T4 (es)
EA (1) EA026619B1 (es)
ES (1) ES2743706T5 (es)
HK (2) HK1206988A1 (es)
HR (1) HRP20191366T4 (es)
HU (1) HUE045979T2 (es)
IL (1) IL235299B (es)
JO (2) JOP20200109A1 (es)
LT (1) LT2841054T (es)
MX (1) MX359241B (es)
MY (2) MY198007A (es)
NZ (1) NZ630335A (es)
PH (2) PH12014502379B1 (es)
PL (1) PL2841054T5 (es)
PT (1) PT2841054T (es)
SG (3) SG10201913425VA (es)
SI (1) SI2841054T2 (es)
TW (5) TW202126303A (es)
UA (1) UA115444C2 (es)
WO (1) WO2013162048A1 (es)
ZA (1) ZA201407335B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
CN105461703B (zh) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 一种brexpiprazole的制备方法
JP6513461B2 (ja) * 2015-04-14 2019-05-15 帝國製薬株式会社 ブレクスピプラゾールの経皮吸収製剤
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
JP6901571B2 (ja) * 2017-01-26 2021-07-14 四川瀛瑞医薬科技有限公司Ｓｉｃｈｕａｎ Ｙｉｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｍｐａｎｙ ナノ炭素−鉄複合システム及びその組成物、調製方法並びに使用
US10987303B2 (en) 2018-05-02 2021-04-27 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
WO2020089942A2 (en) * 2018-11-02 2020-05-07 Amaterasu Lifesciences Llp A liquid injectable composition
WO2021199076A1 (en) * 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
AU2021245713A1 (en) * 2020-04-01 2022-12-01 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
US20230372317A1 (en) * 2020-10-27 2023-11-23 Pts Consulting, Llc A liquid injectable composition of donepezil
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US11910794B2 (en) * 2021-03-08 2024-02-27 Monsanto Technology Llc Solutions and methods for long-term pollen storage
WO2023067664A1 (ja) * 2021-10-18 2023-04-27 大塚製薬株式会社 ベンゾチオフェン化合物の新規結晶形及びその製造方法
CN117529309A (zh) * 2022-06-16 2024-02-06 江苏慧聚药业股份有限公司 药物组合物及依匹哌唑口溶膜
WO2024194955A1 (en) * 2023-03-17 2024-09-26 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864100A (en) * 1957-04-09 1961-03-29 Pfizer & Co C Therapeutic pencillin compositions and the preparation thereof
JPS5913714A (ja) 1982-07-13 1984-01-24 Taito Pfizer Kk 外用消炎鎮痛剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
MY138669A (en) * 2001-09-25 2009-07-31 Otsuka Pharma Co Ltd Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2003171264A (ja) * 2001-12-07 2003-06-17 Taiyo Yakuhin Kogyo Kk マイクロカプセル及びその製造方法
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
BR0313602A (pt) 2002-08-20 2005-06-21 Bristol Myers Squibb Co Método e formulação de complexo de aripiprazol
CN1989968B (zh) 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
BRPI0305500B1 (pt) 2003-01-09 2018-01-23 Otsuka Pharmaceutical Co., Ltd. Processo para preparar aripiprazol
WO2004064752A2 (en) 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
CA2523484A1 (en) * 2003-05-02 2004-11-11 Rimon Therapeutics Ltd. Thermally reversible implant
GEP20084567B (en) 2003-05-23 2008-12-25 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ZA200602347B (en) * 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
EP1677762A1 (en) 2003-10-27 2006-07-12 Dow Corning Corporation A controlled-release composition for topical application and a method of delivering an active agent to a substrate
EP2633853A1 (en) 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
JP2006219380A (ja) * 2005-02-08 2006-08-24 Minofuaagen Seiyaku:Kk グリチルリチン皮下注射製剤
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP2279727A3 (en) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
ES2437581T3 (es) 2005-11-17 2014-01-13 Zogenix, Inc. Suministro de formulaciones viscosas por inyección sin aguja
JP4373983B2 (ja) 2006-01-27 2009-11-25 三菱電機インフォメーションシステムズ株式会社 流通経路管理装置及び流通経路管理プログラム
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
BRPI0720346A2 (pt) * 2006-10-05 2014-06-24 Panacea Biotec Ltd Composições de depósito (depot) injetáveis e processo de preparação dessas composições.
JP4540700B2 (ja) 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
KR101141185B1 (ko) 2007-01-26 2012-07-12 오쓰까 세이야꾸 가부시키가이샤 치료의 제안된 효능 검출용 마커
SG182232A1 (en) 2007-06-25 2012-07-30 Otsuka Pharma Co Ltd Microspheres having core/shell structure
UA97286C2 (ru) 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
JP2011136906A (ja) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
JP2009286740A (ja) 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
TR200809200A1 (tr) 2008-12-01 2009-12-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Meloksikam içeren farmasötik formülasyonlar
US20100316725A1 (en) 2009-05-27 2010-12-16 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
CA2773253A1 (en) 2009-09-11 2011-03-17 Shin-Ichi Niwa Therapeutic agent for chronic pain comprising aripiprazole
MY174552A (en) * 2010-08-24 2020-04-24 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
US9469630B2 (en) * 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
AR083884A1 (es) 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
JP2012121850A (ja) 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
SG191892A1 (en) 2011-01-24 2013-08-30 Otsuka Pharma Co Ltd Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
AR085840A1 (es) 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
JP2012232958A (ja) † 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846543B (zh) * 2011-06-27 2014-11-19 上海中西制药有限公司 一种阿立哌唑药物制剂及其制备方法
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
EP2736894B1 (en) 2011-07-28 2016-08-31 Otsuka Pharmaceutical Co., Ltd. Method for producing benzo[b] thiophene compounds
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
AR088372A1 (es) 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
JP2013139441A (ja) 2011-12-28 2013-07-18 Otsuka Pharmaceut Co Ltd マイクロスフェア
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
PL2841054T3 (pl) 2019-10-31
PH12019500498A1 (en) 2020-03-02
JP2019070028A (ja) 2019-05-09
CN108186556A (zh) 2018-06-22
US20150093442A1 (en) 2015-04-02
KR20210116702A (ko) 2021-09-27
KR20240068788A (ko) 2024-05-17
AU2022241491A1 (en) 2022-10-20
PT2841054T (pt) 2019-09-09
SG10201913425VA (en) 2020-03-30
TW201350136A (zh) 2013-12-16
US20180055941A1 (en) 2018-03-01
KR102498075B1 (ko) 2023-02-10
CN108186556B (zh) 2022-06-10
US12016927B2 (en) 2024-06-25
US20200179517A1 (en) 2020-06-11
CA2869889A1 (en) 2013-10-31
CA3120297A1 (en) 2013-10-31
SI2841054T2 (sl) 2022-05-31
AU2017228608A1 (en) 2017-10-05
JO3632B1 (ar) 2020-08-27
LT2841054T (lt) 2019-09-10
CN104470499B (zh) 2018-03-16
US20210085794A1 (en) 2021-03-25
JOP20200109A1 (ar) 2017-06-16
EA026619B1 (ru) 2017-04-28
WO2013162048A1 (en) 2013-10-31
EP2841054B1 (en) 2019-06-26
UA115444C2 (uk) 2017-11-10
CO7151500A2 (es) 2014-12-29
AU2019200060A1 (en) 2019-01-31
CN114344259A (zh) 2022-04-15
CN104470499A (zh) 2015-03-25
MY178573A (en) 2020-10-16
JP2018048179A (ja) 2018-03-29
DK2841054T4 (da) 2022-06-13
MY198007A (en) 2023-07-25
JP7293412B2 (ja) 2023-06-19
JP2021008512A (ja) 2021-01-28
JP2022050619A (ja) 2022-03-30
US10517951B2 (en) 2019-12-31
SI2841054T1 (sl) 2019-09-30
AU2020204200B2 (en) 2022-06-30
US11097007B2 (en) 2021-08-24
KR20200064173A (ko) 2020-06-05
CY1122252T1 (el) 2020-11-25
ES2743706T5 (es) 2022-05-25
AU2017228608C1 (en) 2019-02-21
BR112014026307B1 (pt) 2022-10-11
AU2017228608B2 (en) 2018-10-18
US20190099494A1 (en) 2019-04-04
BR112014026307A2 (pt) 2017-06-27
AU2020204200A1 (en) 2020-07-16
CA2869889C (en) 2021-07-20
JP6234996B2 (ja) 2017-11-22
KR102138852B1 (ko) 2020-07-28
SG10201608753UA (en) 2016-12-29
PH12014502379A1 (en) 2015-01-12
TW202425992A (zh) 2024-07-01
US20230390399A1 (en) 2023-12-07
MX2014012811A (es) 2015-05-07
HUE045979T2 (hu) 2020-01-28
IL235299A0 (en) 2014-12-31
HK1206988A1 (en) 2016-01-22
EP2841054A1 (en) 2015-03-04
HK1257028A1 (zh) 2019-10-11
US20220096638A1 (en) 2022-03-31
TW202313036A (zh) 2023-04-01
CN114344259B (zh) 2024-02-13
ZA201407335B (en) 2019-06-26
TWI713826B (zh) 2020-12-21
US20190336607A1 (en) 2019-11-07
PL2841054T5 (pl) 2022-07-18
JP6470378B2 (ja) 2019-02-13
SG11201406451SA (en) 2014-11-27
KR20150003861A (ko) 2015-01-09
TWI637752B (zh) 2018-10-11
PH12014502379B1 (en) 2015-01-12
JP2023113806A (ja) 2023-08-16
JP2015514751A (ja) 2015-05-21
HRP20191366T4 (hr) 2022-08-19
NZ630335A (en) 2016-07-29
AR090776A1 (es) 2014-12-03
EP3539534A1 (en) 2019-09-18
IL235299B (en) 2019-12-31
DK2841054T3 (da) 2019-09-09
US11638757B2 (en) 2023-05-02
HRP20191366T1 (hr) 2019-12-27
TW202126303A (zh) 2021-07-16
EA201491685A1 (ru) 2015-04-30
AU2013253374A1 (en) 2014-10-23
AU2013253374B2 (en) 2017-06-15
TW201900174A (zh) 2019-01-01
ES2743706T3 (es) 2020-02-20
EP2841054B2 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
PH12019500498A1 (en) Injectable preparation
MY161022A (en) Dexmedetomidine premix formulation
SG196810A1 (en) Controlled release pharmaceutical or foodformulation and process for its preparation
JO2944B1 (en) Long-acting formulations of insulin
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112013016770A2 (pt) formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica
MX2013002932A (es) Formulaciones agricolas liquidas de estabilidad mejorada.
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
MX2016005395A (es) Formulacion estable de insulina glulisina.
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
MX2013008433A (es) Dispositivo medico que contiene una composicion en torta que comprende aripiprazol como ingrediente activo, y una composicion en torta que comprende aripirazol como ingrediente activo.
EP4282272A3 (en) Method of delivering an agriculturally active ingredient
MX2016001422A (es) Composicion farmaceutica de fingolimod.
TN2012000516A1 (en) Stable ready to use injectable paracetamol formulation
MX2015015075A (es) Dispositivo de administracion de farmaco y metodo de ensamblaje del mismo.
RS54013B1 (en) HIGH-ELASTIC GELS IN OPTAMOLOGICAL SURGERY
IN2012CH05549A (es)
MX2021015921A (es) Preparacion inyectable.
MX2013014125A (es) Una composicion que comprende por lo menos un alginato para el uso en el tratamiento y/o prevencion de sobrepeso.
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
Choi et al. Super-Tough Hybridgels Comprising of Mesoporous Silica Microrods and Double-Network Polymers for On-Demand Drug Delivery by Mechanical Stimulation
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
EA027609B9 (ru) Способ получения интерферона бета-1альфа и фармацевтическая композиция, содержащая интерферон бета-1альфа
IN2013CH01615A (es)

Legal Events

Date Code Title Description
FG Grant or registration